Halazepam
Template:Short description Template:Drugbox
Halazepam is a benzodiazepine derivative that was marketed under the brand names Paxipam in the United States,[1] Alapryl in Spain,[2] and Pacinone in Portugal.[3]
Medical uses
Halazepam was used for the treatment of anxiety.[1]
Adverse effects
Adverse effects include drowsiness, confusion, dizziness, and sedation. Gastrointestinal side effects have also been reported including dry mouth and nausea.[1]
Pharmacokinetics and pharmacodynamics
Pharmacokinetics and pharmacodynamics were listed in Current Psychotherapeutic Drugs published on June 15, 1998 as follows:[4]
| Onset of action | Intermediate to slow |
| Plasma half life | 14 hr for parent drug and 30-100 hr for its metabolite |
| Peak plasma levels | 1-3 hr for parent drug and 3-6 hf for its metabolite |
| Metabolism | Metabolized into desmethyldiazepam and 3-hydroxyhalazepam (in the liver) |
| Excretion | Excreted through kidneys |
| Protein binding | 98% bound to plasma protein |
Regulatory Information
Halazepam is classified as a schedule 4 controlled substance with a corresponding code 2762 by the Drug Enforcement Administration (DEA).[5]
Commercial production
Halazepam was invented by Schlesinger Walter in the U.S. It was marketed as an anti-anxiety agent in 1981. However, Halazepam is not commercially available in the United States because it was withdrawn by its manufacturer for poor sales.[1]
See also
- Benzodiazepines
- Nordazepam
- Diazepam
- Chlordiazepoxide
- Quazepam, fletazepam, triflubazam — benzodiazepines with trifluoromethyl group attached
References
<templatestyles src="Reflist/styles.css" />
Script error: No such module "Check for unknown parameters".
External links
Script error: No such module "Navbox". Script error: No such module "navbox". Template:GABAAR PAMs